Oral Proteins and Peptides Market By Drug Type (Insulin and Analogues, Somatropin, Calcitonin, Interferons, Others); By Application (Diabetes, Hormonal Disorders, Cancer, Infectious Diseases, Genetic Disorders, Others); By Dosage Form (Tablets, Capsules, Liquid Oral Formulations); By End User (Hospitals, Specialty Clinics, Research and Academic Institutes, Home Care Settings); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Oral Proteins and Peptides Market: Transforming the Future of Oral Biologics

The global oral proteins and peptides market was valued at $1.3 Bn in 2023 & is projected to grow at a CAGR of 9.5% from 2024 to 2030, potentially reaching $2.5 billion by 2030. The rising prevalence of diabetes and hormonal disorders are expected to fuel market expansion.

 

The oral peptides & proteins and  market is a rapidly growing sector in the pharmaceutical industry. It is focused on the development of oral formulations of protein and peptide-based drugs. North America currently leads the market, whereas the APAC region is expected to encounter the fastest growth due to increase in healthcare investments and a growing patient pool.

 

Oral Proteins and Peptides Market Dynamics: Exploring Trends and Emerging Opportunities

Oral Proteins and Peptides Market Drivers: The Push Towards Patient-Friendly Therapies

Rising Prevalence of Chronic Diseases: The increasing rates of diseases like diabetes, cancer, and hormonal disorders creates the need for oral protein and peptide-based medicines. The IDF established that the global population of people living with diabetes will rise to 783 million by 2045, calling for innovative interventions to treat this condition.

Advancements in Drug Delivery Technologies: Recent advancements in technologies, nanoparticles, permeability boosters, and protease inhibitors facilitate the oral delivery of proteins and peptides. The enzymatic degradation and poor absorption of insulin presented by Novo Nordisk and Oramed Pharmaceuticals use an insulin formulation that solves these problems.

 

Oral Proteins and Peptides Market Opportunities: Pioneering Growth in Precision Medicine

Rising Focus on Patient-Friendly Drug Delivery: The rising demand for effective topical noninterference therapy, patient compliance, and safety further increases the demand for oral protein and peptide formulations rather than injections. Insulin and GLP-1 receptor agonists in the form of oral tablets are entering the market, focusing on better ease for diabetic patients.

Expansion in Emerging Markets: Emerging economies in Asia-Pacific and several Latin American nations represent great opportunities to invest in healthcare due to rising costs, a higher rate of chronic diseases, and growth in pharmaceutical production.

 

Oral Proteins and Peptides Market Challenges: Overcoming Barriers in Oral Bioavailability

Low Bioavailability and Stability Challenges: Proteins and peptides have poor stability, especially to enzymatic degradation, which leads to low bioavailability and efficacy. Most oral formulations need special and rigorous production processes that can significantly increase the costs of stability and absorption.

 

High Development Costs: Oral protein and peptide drugs require capital investments in Research and development, which would present strategic barriers to small players in the industry. It may take 10 - 15 years to develop a biological drug, and it can cost over $2 billion to bring it to the market; this creates financial constraints on market entrants.

 

 

Oral Proteins and Peptides Market Segmentation: Mapping the Key Growth Categories

By Drug Type

• Insulin and Analogues

• Somatropin

• Calcitonin

• Interferons

• Others

 

By Application

• Diabetes

• Hormonal Disorders

• Cancer

• Infectious Diseases

• Genetic Disorders

• Others

 

By Dosage Form

• Tablets

• Capsules

• Liquid Oral Formulations

 

By End User

• Hospitals

• Specialty Clinics

• Research and Academic Institutes

• Home Care Settings

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Oral Proteins and Peptides Market Segment Analysis: Spotlight on Leading Therapeutic Applications

Leading Segment: By Drug Type

Insulin and its analogs are the most significant products in the oral peptides and proteins market because of the high incidence of diabetes and the development of oral insulin formulations. This segment is characterized by the necessity of creating patient-friendly solutions to replace injectable insulin. Diabetes currently impacts half a billion adults and is predicted to rise to 640 million in the next 10 years (IDF, 2023), hence the importance of insulin in chronic disease.

 

Leading Segment: By Application

The diabetes application segment has a market share of more than 45% due to the conversion from injecting to oral delivery. Diabetes has continued to be the largest application area because of the growing incidence of diabetes globally and the efficacy of proteins such as insulin and GLP-1 receptor agonists in treating it. Novo Nordisk’s Rybelsus ODT, known as oral semaglutide, is now the benchmark for oral diabetes medications.

 

Leading Segment: By Dosage Form

Tablets hold fifty percent of the market and are considered the key platform for new orally administered protein products. They are very flexible and easily administered, with high patient compliance compared to injectable or capsule dosage forms. ORMD-0801 is an oral insulin tablet made by Oramed Pharmaceuticals, which has yielded positive outcomes in its clinical trial.

 

Leading Segment: By End User

Hospitals alone account for about 40% of the total market because they are indispensable in responding to patients’ needs and administering trials. The medication's oral peptide formulation is approved by health insurers, and large health systems such as the Mayo Clinic and Cleveland Clinic are preparing to prescribe new oral peptide therapies.

 

Leading Regions:

North America has a market stake of about 40%, with the United States having the largest stake. Lilly has already committed a significant amount of money to launch two biologics platforms in the United States, while Amgen recently announced plans to invest $4.2 billion to develop a new portfolio of oral products.

 

Oral Proteins and Peptides Market Key Players: Driving Innovation in Oral Biologics Delivery

• Novo Nordisk

• Oramed Pharmaceuticals

• Eli Lilly and Company

• Amgen Inc.

• AstraZeneca

• Sanofi

• Pfizer Inc.

• Biocon Limited

• Rani Therapeutics

• Chiasma, Inc.

 

Oral Proteins and Peptides Market Report Coverage

Report Attribute	Details
Forecast Period	2023 – 2030
Market Size Value in 2023	USD 1.3 Billion
Revenue Forecast in 2030	USD 2.5 Billion
Overall Growth Rate	CAGR of 9.5%
Base Year for Estimation	2022
Historical Data	2017 – 2021
Unit	USD Million, CAGR (2023 – 2030)
Segmentation	By Drug Type, By Application, By Dosage Form, By End User, By Region
By Drug Type	Insulin and Analogues, Somatropin, Calcitonin, Interferons, Others
By Application	Diabetes, Hormonal Disorders, Cancer, Infectious Diseases, Genetic Disorders, Others
By Dosage Form	Tablets, Capsules, Liquid Oral Formulations
By End User	Hospitals, Specialty Clinics, Research Institutes, Home Care Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	US, Canada, UK, Germany, France, China, Japan, India, etc.
Pricing and Purchase Options	Customized options available

 

Future Outlook

Oral proteins and peptides market has projected great prospects for the future boosted by the innovations in drug delivery systems such as nanoparticle encapsulation and robotic pills. North America will remain as a market leader due to increase in the R&D intensity as well as adoption of novel or high-tier biologics in future. However, there are challenges that can hinder the growth of this market, key of which include, high development costs, and high regulatory requirements that are associated with the development of new drugs On the same note, the global market for patient-centric and non-invasive therapies will continue to experience rapid growth.